Kenya - English - Pharmacy and Poisons Board

pharmaken ltd p.o box 95625-80106 - sacubitril 49mg / valsartan 51mg - tablet - sacubitril 49mg / valsartan 51mg - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

pharmaken ltd p.o box 95625-80106 - sacubitril 24mg / valsartan 26mg - tablet - sacubitril 24mg / valsartan 26mg - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 49mg and valsartan 51mg tablets - tablet - sacubitril 49mg and valsartan 51mg tablets - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 97mg and valsartan 103mg tablets - tablet - sacubitril 97mg and valsartan 103mg tablets - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

innocia lifesciences pvt ltd innocia lifesciences pvt ltd - sacubitril 24mg and valsartan 26mg tablets - tablet - sacubitril 24mg and valsartan 26mg tablets - valsartan and sacubitril

Kenya - English - Pharmacy and Poisons Board

sacubitril valsartan sodium on colloidal silicon… - film-coated tablet - sacubitril 49mg valsartan sodium 51mg on… - valsartan and sacubitril

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; purified talc; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 50mg (as sodium hydrate complex, contains 24.3 mg sacubitril and 25.7 mg valsartan);  ;   - film coated tablet - 24.3 mg/25.7 mg - active: sacubitril/valsartan 50mg (as sodium hydrate complex, contains 24.3 mg sacubitril and 25.7 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating premix, white basic coating premix, red basic coating premix, black magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan);  ;   - film coated tablet - 48.6 mg/51.4 mg - active: sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating premix, white basic coating premix, yellow basic coating premix, red magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan);  ;   - film coated tablet - 97.2 mg/102.8 mg - active: sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating mixture, white basic coating mixture, red basic coating mixture, black magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat